Nā huahana
-
Givosiran
ʻO Givosiran API kahi RNA interfering liʻiliʻi liʻiliʻi (siRNA) i aʻo ʻia no ka mālama ʻana i ka porphyria hepatic acute (AHP). Kuhi nui ia i kaALAS1gene (aminolevulinic acid synthase 1), i komo i ke ala biosynthesis heme. Hoʻohana nā mea noiʻi iā Givosiran e noiʻi i nā lāʻau lapaʻau e pili ana i ka RNA interference (RNAi), silencing gene i hoʻopaʻa ʻia i ka ate, a me ka modulation o nā ala metabolic e pili ana i ka porphyria a me nā maʻi genetic pili.
-
Pegcetacoplan
ʻO Pegcetacoplan kahi peptide cyclic pegylated e hana ana ma ke ʻano he C3 complement inhibitor, i hoʻomohala ʻia no ka mālama ʻana i nā maʻi complement-mediated e like me ka paroxysmal nocturnal hemoglobinuria (PNH) a me ka geographic atrophy (GA) i ka macular degeneration pili makahiki.
-
Plozasiran
ʻO Plozasiran API kahi RNA interfering liʻiliʻi liʻiliʻi (siRNA) i hoʻomohala ʻia no ka mālama ʻana i ka hypertriglyceridemia a me nā maʻi cardiovascular a me ka metabolic pili. Huli ia i kaAPOC3gene, ka mea e hoʻopili i ka apolipoprotein C-III, kahi mea hoʻoponopono koʻikoʻi o ka metabolism triglyceride. I ka noiʻi ʻana, hoʻohana ʻia ʻo Plozasiran e aʻo i nā hoʻolālā hoʻohaʻahaʻa lipid e pili ana i ka RNAi, ka kikoo-silencing kikoʻī, a me nā lāʻau lōʻihi no nā kūlana e like me ka familial chylomicronemia syndrome (FCS) a me ka dyslipidemia hui ʻia.
-
Zilebesiran
ʻO Zilebesiran API kahi noiʻi liʻiliʻi liʻiliʻi interfering RNA (siRNA) i kūkulu ʻia no ka mālama ʻana i ka hypertension. Huli ia i kaAGTgene, e hoʻopili ana i ka angiotensinogen—he mea nui o ka ʻōnaehana renin-angiotensin-aldosterone (RAAS). Ma ka noiʻi, hoʻohana ʻia ʻo Zilebesiran e aʻo i nā ala hoʻoheheʻe gene no ka mālama ʻana i ke koko lōʻihi, nā ʻenehana lawe RNAi, a me ka hana ākea o ke ala RAAS i nā maʻi cardiovascular a me ka renal.
-
Palopegteriparatide
ʻO ka Palopegteriparatide kahi agonist hormone receptor agonist lōʻihi (PTH1R agonist), i hoʻomohala ʻia no ka mālama ʻana i ka hypoparathyroidism mau loa. He analog pegylated o PTH (1-34) i hoʻolālā ʻia e hāʻawi i ka hoʻoponopono calcium hoʻomau me ka hoʻopaʻa ʻana i hoʻokahi pule.
-
GHRP-6
ʻO GHRP-6 (Growth Hormone Releasing Peptide-6) he hexapeptide synthetic e hana ana ma ke ʻano he secretagogue hormone ulu, e hoʻoulu ana i ka hoʻokuʻu maoli ʻana o ke kino o ka hormone ulu (GH) ma ka hoʻoulu ʻana i ka GHSR-1a receptor.
Nā hiʻohiʻona API:
Maʻemaʻe ≥99%
Hana ʻia ma o ka solid-phase peptide synthesis (SPPS)
Hāʻawi ʻia no ka R&D a me ka hoʻohana ʻana i ka ʻoihana
ʻO GHRP-6 kahi peptide noiʻi maʻamau no ke kākoʻo metabolic, hoʻoulu hou ʻana i ka ʻiʻo, a me ka modulation hormonal.
-
GHRP-2
ʻO GHRP-2 (Growth Hormone Releasing Peptide-2) he hexapeptide synthetic a me ka potent growth hormone secretagogue, i hoʻolālā ʻia e hoʻoulu i ka hoʻokuʻu kūlohelohe o ka hormone ulu (GH) ma o ka hoʻoulu ʻana i ka GHSR-1a receptor i ka hypothalamus a me ka pituitary.
Nā hiʻohiʻona API:
Maʻemaʻe ≥99%
Loaʻa no ka R&D a me ka lako kalepa, me ka palapala QC piha
ʻO GHRP-2 kahi peptide noiʻi koʻikoʻi ma nā kahua o ka endocrinology, lāʻau lapaʻau hou, a me nā lāʻau lapaʻau pili makahiki.
-
Hexarelin
ʻO Hexarelin kahi synthetic growth hormone secretagogue peptide (GHS) a me ka potent GHSR-1a agonist, i hoʻomohala ʻia e hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu (GH). No ka ʻohana mimetic ghrelin a ua haku ʻia me ʻeono amino acids (hexapeptide), e hāʻawi ana i ka hoʻomaikaʻi ʻana i ka metabolic stability a me nā hopena hoʻokuʻu GH ikaika i hoʻohālikelike ʻia me nā analogs mua e like me GHRP-6.
Nā hiʻohiʻona API:
Maʻemaʻe ≥ 99%
Hana ʻia ma o ka solid-phase peptide synthesis (SPPS)
Nā kūlana like GMP, endotoxin haʻahaʻa a me nā koena solvent
Hāʻawi maʻalahi: R&D i ka pālākiō kalepa
-
Melanotana II
Nā hiʻohiʻona API:
Maʻemaʻe kiʻekiʻe ≥ 99%
Hoʻopili ʻia ma o ka solid-phase peptide synthesis (SPPS)
Haʻahaʻa endotoxin, haʻahaʻa koena solvents
Loaʻa ma R&D i ka pālākiō pāʻoihana -
Melanotana 1
Hana ʻia ʻo Melanotan 1 API me ka hoʻohana ʻana i ka ʻenehana solid phase peptide synthesis (SPPS) ma lalo o nā kūlana mana maikaʻi e like me GMP.
-
Maʻemaʻe kiʻekiʻe ≥99%
-
ʻO ka hoʻohuihui peptide-phase paʻa (SPPS)
-
Nā kūlana hana like GMP
-
Nā palapala piha: COA, MSDS, ʻikepili paʻa
-
Hiki ke hoʻolako ʻia: R&D i nā pae pāʻoihana
-
-
MOTS-C
Hoʻokumu ʻia ka MOTS-C API ma lalo o nā kūlana GMP-like koʻikoʻi me ka hoʻohana ʻana i ka ʻenehana solid phase peptide synthesis (SPPS) e hōʻoia i kona kiʻekiʻe kiʻekiʻe, kiʻekiʻe maʻemaʻe a me ke kūpaʻa kiʻekiʻe no ka noiʻi a me ka hoʻohana therapeutic.
Nā hiʻohiʻona huahana:Maʻemaʻe ≥ 99% (hōʻoia ʻia e HPLC a me LC-MS),
ʻO ka endotoxin haʻahaʻa a me ke koena o ka solvent content,
Hana ʻia e like me ICH Q7 a me GMP-like protocols,
Hiki ke hoʻokō i ka hana nui, mai ka milligram-level R&D pūʻulu a hiki i ka gram-level a me ka kilokani-level lako kalepa. -
Ipamorelin
Hoʻomākaukau ʻia ʻo Ipamorelin API e ke kūlana kiʻekiʻe **solid phase peptide synthesis process (SPPS)** a hoʻomaʻemaʻe koʻikoʻi a me ka hoʻāʻo maikaʻi, kūpono no ka hoʻohana mua ʻana i ka pipeline i ka noiʻi ʻepekema a me ka hoʻomohala ʻana a me nā hui lāʻau lapaʻau.
Loaʻa nā hiʻohiʻona huahana:
Maʻemaʻe ≥99% (HPLC ho'āʻo)
ʻAʻohe endotoxin, haʻahaʻa koena solvent, haʻahaʻa metala ion contamination
Hāʻawi i kahi pūʻulu piha o nā palapala maikaʻi: COA, hōʻike hoʻopaʻa haʻawina paʻa, ka nānā ʻana i ka spectrum haumia, etc.
Hiki ke hoʻolako i ka pae gram-level~kilogram-level